Memento

Show / Hide search form
Menu

U.S. CDMRP – Breast Cancer Research Program | Research Funding

Thumbnail

Event details

Date 12.06.2026
Category Call for proposal
Event Language English
Aim: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the 2026 Breast Cancer Research Program (BCRP) Awards. Several award programs are available:
  • The Breakthrough Awards supports promising research that has high potential to lead to or make breakthroughs in breast cancer. The Breakthrough Award is structured with four different funding levels. Each level has a defined research scope :
    • Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development or is an untested theory that addresses an important problem.
    • Funding Level 2: Research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within the breast cancer landscape.
    • Funding Level 3: Advanced translational studies with a high degree of project readiness.
    • Funding Level 4: Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Human clinical trials are required.
  • The Clinical Research Extension Award aims to extend the data collection, follow-up, and analysis of breast cancer clinical research studies. Proposed research may entail a deeper molecular analysis of clinical samples, initiation of new correlative studies, biomarker validation, or continuing clinical follow-up of patients currently/previously enrolled in an open/ongoing or completed clinical trial.
  • The Era of Hope Scholar Award supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer. These individuals should be exceptionally talented scientists who have shown that they are the “best and brightest” in their field(s)
  • The Transformative Breast Cancer Consortium Award is designed to support large-scale, multidisciplinary and multi-institutional consortia that address major challenges in breast cancer through tightly integrated and collaborative research efforts. It enables up to five Principal Investigators, including a Consortium Director, to work within a coordinated framework where all project components are aligned toward a shared central hypothesis. The award specifically aims to foster innovative and paradigm-shifting approaches that go beyond the capabilities of individual laboratories, requiring strong integration across scientific, administrative, and logistical aspects, as well as the active involvement of breast cancer advocates and cross-disciplinary expertise.
  • The Transformative Breast Cancer Consortium Development Award is intended to provide successful applicants the time and resources needed to bring investigators and breast cancer advocates together to establish a consortium framework and conduct preliminary research to support application to a future, full Transformative Breast Cancer Consortium Award (pending availability of funds). This is a development award and is a separate mechanism from the full consortium award. Recipients of the FY26 Transformative Breast Cancer Consortium Development Award are expected to submit an application to compete for the full Transformative Breast Cancer Consortium Award anticipated to be offered in a future fiscal year(s).

All applications must align with at least one BCRP Overarching Challenge. The FY26 BCRP Challenges are listed at the end of this announcement.

Funding:      
Breakthrough 1: $750K - $1.25M
Breakthrough 2: $1.65M - $3.35M
Breakthrough 3: $5.6M - $7M
Breakthrough 4: max. $21M
Clinical Research Extension: $7M - $8.4M
Era of Hope: max. $4.9M
Transformative Breast Cancer Consortium Award: max. $35M
Transformative Breast Cancer Consortium Development Award: max. $140K
Note: Cost caps are total costs (direct plus indirect costs). In accordance with EPFL guidelines, budgets should include a 20% overhead, and the total budget must remain within the grant’s maximum allowable funding.

Duration:     
Breakthrough 1: 3 years
Breakthrough 2: 3-4 years
Breakthrough 3: 4 years
Breakthrough 4: 4 years
Clinical Research Extension: 4 years
Era of Hope: 4 years
Transformative Breast Cancer Consortium Award: 4 years
Transformative Breast Cancer Consortium Development Award: 1 year

Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Programme-specific seniority levels are further defined here.

How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.

Pre-Application Deadline:           
  • 12 June 2026, 5:00 p.m. Eastern time
    • Breakthrough Award Level 3
    • Breakthrough Award Level 4
    • Transformative Breast Cancer Consortium Award
  • 24 June 2026, 5:00 p.m. Eastern time
    • Breakthrough Award Level 1-2
    • Transformative Breast Cancer Consortium Development Award
    • Clinical Research Extension Award
    • Era of Hope Scholar Award

Full Application Deadline:          
  • 08 July 2026, 11:59 p.m. Eastern time
    • Breakthrough Award Level 1-2
    • Transformative Breast Cancer Consortium Development Award
    • Clinical Research Extension Award
    • Era of Hope Scholar Award
  • 30 September 2026, 11:59 p.m. Eastern time
    • Breakthrough Award Level 3
    • Breakthrough Award Level 4
    • Transformative Breast Cancer Consortium Award

Further information:
FY26 BCRP Overarching Challenges
  • Prevent breast cancer (primary prevention)
  • Identify determinants of breast cancer initiation, risk, or susceptibility
  • Distinguish deadly from non-deadly breast cancers
  • Conquer the problems of overdiagnosis and overtreatment
  • Identify what drives breast cancer growth; determine how to stop it
  • Identify why some breast cancers become metastatic
  • Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
  • Revolutionize treatment regimens by replacing them with ones that do all of the following: improve survival, are more effective, and are less toxic
  • Eliminate the mortality associated with metastatic breast cancer
Alternatively, with adequate justification, applications may identify and address another overarching challenge related to The Breast Cancer Landscape. Justification must be provided in the application.
 

Practical information

  • General public
  • Free

Contact

Export Event

Event broadcasted in

Share